Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a positive regulatory update from its recent Type C meeting with the U.S. FDA that supports the continued advancement of SGT-003 as a potential treatment for Duchenne muscular dystrophy.
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003 (BioSpace)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy (Duchenne), has been granted an Innovation Passport under the new ILAP.
Solid Biosciences Reports Positive Initial Clinical Data From Next-Generation Duchenne Gene Therapy Candidate SGT-003
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy candidate for treating Duchenne muscular dystrophy.
Solid Biosciences Shares Updates on Inspire Duchenne Clinical Trial of SGT-003
Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, shared updates on the INSPIRE DUCHENNE clinical trial for their next-generation AAV micro-dystrophin gene therapy candidate, SGT-003, for the treatment of Duchenne.
JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential
JPMorgan upgraded Solid Biosciences stock, a biotechnology company that acquired UF startup AavantiBio, from Neutral to Overweight, and increased the price target to $15.00 from the previous $10.00. The firm’s decision reflects a positive outlook on the company’s prospects, particularly with upcoming developments expected in the fourth quarter.